Treats known or suspected opioid overdose. ANDA 211951, held by Padagis Israel. Naloxone Hydrochloride.
As of Nov 22, 2026, ANDA 211951 (Naloxone Hydrochloride), held by Padagis Israel, was first approved by FDA on Jun 21, 2022, with 1 approved supplement and 0 published complete response letters.
Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of naloxone hydrochloride nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 21, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Naloxone Hydrochloride4MG/SPRAY · spray, metered;nasal | Naloxone Hydrochloride | OTC |
| Jul 18, 2023 | Supplement 3Labeling · Standard review | Approved | |
| Jun 21, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters